KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

West Pharmaceutical Services (WST) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to 19.45%.

  • West Pharmaceutical Services' EBITDA Margin fell 18600.0% to 19.45% in Q4 2025 from the same period last year, while for Dec 2025 it was 19.03%, marking a year-over-year decrease of 6700.0%. This contributed to the annual value of 19.03% for FY2025, which is 6700.0% down from last year.
  • As of Q4 2025, West Pharmaceutical Services' EBITDA Margin stood at 19.45%, which was down 18600.0% from 20.83% recorded in Q3 2025.
  • In the past 5 years, West Pharmaceutical Services' EBITDA Margin ranged from a high of 29.61% in Q2 2022 and a low of 15.33% during Q1 2025
  • For the 5-year period, West Pharmaceutical Services' EBITDA Margin averaged around 22.67%, with its median value being 21.83% (2023).
  • In the last 5 years, West Pharmaceutical Services' EBITDA Margin soared by 95500bps in 2021 and then plummeted by -68800bps in 2022.
  • Quarter analysis of 5 years shows West Pharmaceutical Services' EBITDA Margin stood at 25.18% in 2021, then decreased by -27bps to 18.3% in 2022, then rose by 20bps to 21.98% in 2023, then fell by -3bps to 21.31% in 2024, then dropped by -9bps to 19.45% in 2025.
  • Its EBITDA Margin was 19.45% in Q4 2025, compared to 20.83% in Q3 2025 and 20.05% in Q2 2025.